Table. Patient Baseline Characteristics According to Presence of Prior Stroke, Transient Ischemic Attack, or Thromboembolism.
| No./total No. (%) | P value | |||
|---|---|---|---|---|
| Overall (n = 4581) | Prior stroke/TIA/TE (n = 633) | No prior stroke/TIA/TE (n = 3948) | ||
| Age, median (IQR), y | 71 (64-77) | 72 (66-78) | 70 (64-77) | <.001 |
| Female sex | 1329/4581 (29.0) | 183/633 (28.9) | 1146/3948 (29.0) | .95 |
| Male sex | 3252/4581 (71.0) | 450/633 (71.1) | 2802/3948 (71.0) | |
| Race and ethnicitya | .17 | |||
| American Indian and Alaska Native | 16/4524 (0.4) | 3/624 (0.5) | 13/3900 (0.3) | |
| Asian | 140/4524 (3.1) | 20/624 (3.2) | 120/3900 (3.1) | |
| Black | 59/4524 (1.3) | 14/624 (2.2) | 45/3900 (1.2) | |
| White | 4152/4524 (91.8) | 570/624 (91.3) | 3582/3900 (91.8) | |
| Other | 157/4524 (3.5) | 17/624 (2.7) | 140/3900 (3.6) | |
| Serum creatinine, mg/dL | .61 | |||
| <1.5 | 4128/4504 (91.7) | 565/620 (91.1) | 3563/3884 (91.7) | |
| ≥1.5 | 376/4504 (8.3) | 55/620 (8.9) | 321/3884 (8.3) | |
| CHA2DS2-VASc score, mean (SD) | 3.9 (1.6) | 5.9 (1.4) | 3.6 (1.3) | <.001 |
| HAS-BLED score, mean (SD) | 2.9 (0.9) | 3.7 (1.0) | 2.7 (0.9) | <.001 |
| Prior bleeding | 50/4561 (1.1) | 16/632 (2.5) | 34/3929 (0.9) | <.001 |
| Hypertension leading to medication use | 4073/4581 (88.9) | 576/633 (91.0) | 3497/3948 (88.6) | .07 |
| Heart failure | 1973/4581 (43.1) | 301/633 (47.6) | 1672/3948 (42.4) | .01 |
| Diabetes | 1678/4581 (36.6) | 264/633 (41.7) | 1414/3948 (35.8) | .004 |
| Concomitant P2Y12 inhibitor at randomization | .09 | |||
| Clopidogrel | 4142/4469 (92.7) | 557/615 (90.6) | 3585/3854 (93.0) | |
| Prasugrel | 49/4469 (1.1) | 8/615 (1.3) | 41/3854 (1.1) | |
| Ticagrelor | 278/4469 (6.2) | 50/615 (8.1) | 228/3854 (5.9) | |
| Previous use of oral anticoagulant | 2247/4581 (49.1) | 344/633 (54.3) | 1903/3948 (48.2) | .004 |
| Qualifying index event | .38 | |||
| ACS and PCI | 1705/4564 (37.4) | 222/629 (35.3) | 1483/3935 (37.7) | |
| Medically managed ACS | 1095/4564 (24.0) | 163/629 (25.9) | 932/3935 (23.7) | |
| Elective PCI | 1764/4564 (38.7) | 244/629 (38.8) | 1520/3935 (38.6) | |
| No. of days from ACS or PCI to randomization, mean (SD) | 6.6 (4.2) | 7.0 (4.2) | 6.6 (4.2) | .006 |
| Reduced-dose apixaban (2.5 mg) in patients randomized to receive apixaban | 227/2274 (10.0) | 37/324 (11.4) | 190/1950 (9.7) | .35 |
Abbreviations: ACS, acute coronary syndrome; PCI, percutaneous coronary intervention; TE, thromboembolism; TIA, transient ischemic attack.
SI conversion factor: To convert creatinine to μmol/L, multiply by 88.4.
a
Race and ethnicity data for the patients were determined by the investigator and recorded on the case-report forms. The category other includes those not in the other listed groups.